Dr. Elias Mai discusses the results of the GMMG-HD7 phase 3 trial, which evaluated the efficacy of adding isatuximab, an antibody targeting CD38, to standard therapy for newly diagnosed multiple myeloma patients.
Link to ASH playlist: [ Ссылка ]
ASH Abstract: Impact of Minimal Residual Disease on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy in the Phase 3 GMMG-HD7 Trial
#ASH24 #myeloma #mmsm
Follow HealthTree:
[ Ссылка ]
twitter.com/healthtreeformm
facebook.com/healthtreeformultiplemyeloma
instragram.com/healthtreeformultiplemyeloma
